Yahoo
Milan - Delayed Quote EUR

Pharmanutra S.p.A. (PHN.MI)

71.00 -1.00 (-1.39%)
At close: October 30 at 5:35:06 PM GMT+1
Chart Range Bar
Loading chart for PHN.MI
  • Previous Close 72.00
  • Open 71.80
  • Bid 70.90 x --
  • Ask 71.30 x --
  • Day's Range 70.60 - 72.20
  • 52 Week Range 43.55 - 95.90
  • Volume 13,714
  • Avg. Volume 13,086
  • Market Cap (intraday) 679.838M
  • Beta (5Y Monthly) 0.18
  • PE Ratio (TTM) 33.18
  • EPS (TTM) 2.14
  • Earnings Date (est.) --
  • Forward Dividend & Yield 1.20 (1.69%)
  • Ex-Dividend Date May 4, 2026
  • 1y Target Est 95.67

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It offers Sucrosomial, a delivery system that optimises nutrient transport and absorption for minimising gastrointestinal side effects; and Cetylated Fatty Acids, a formulation for muscle and joint recovery in physiotherapy and sports. The company also sells instrumentation and software for body bioimpedance analysis through agents, distributors, and online sales. Pharmanutra S.p.A. was founded in 2000 and is headquartered in Pisa, Italy.

www.pharmanutra.it

144

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is FTSE MIB Index (FTSEMIB.MI) .

YTD Return

PHN.MI
32.78%
FTSE MIB Index (FTSEMIB.MI)
10.14%

1-Year Return

PHN.MI
56.06%
FTSE MIB Index (FTSEMIB.MI)
14.58%

3-Year Return

PHN.MI
53.77%
FTSE MIB Index (FTSEMIB.MI)
81.06%

5-Year Return

PHN.MI
12.74%
FTSE MIB Index (FTSEMIB.MI)
84.18%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings 5.99M
Profit Margin 0.00%

Q4

FY24

Q1

FY25

Q3

FY25

Q4

FY25

0
10M
20M
30M
0.0%
2.0%
4.0%
6.0%
8.0%
10.0%

Analyst Insights

View More

Analyst Price Targets

92.00
95.67 Average
71.00 Current
102.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.44%

  • Return on Assets (ttm)

    16.19%

  • Return on Equity (ttm)

    31.60%

  • Revenue (ttm)

    143.7M

  • Net Income Avi to Common (ttm)

    20.74M

  • Diluted EPS (ttm)

    2.14

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    15.14M

  • Total Debt/Equity (mrq)

    26.40%

  • Levered Free Cash Flow (ttm)

    15.65M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: